Sonpavde Guru, Spencer David M, Slawin Kevin M
U.S. Oncology Research and the Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77598, USA.
Urol Oncol. 2007 Nov-Dec;25(6):451-9. doi: 10.1016/j.urolonc.2007.01.010.
Immunotherapy with vaccines represents a novel, targeted nontoxic modality for the therapy of prostate cancer. Systemic immune responses to candidate prostate cancer antigens have been induced in a tumor that has been conventionally viewed as refractory to immunotherapy. Autologous dendritic cell vaccines expressing prostate-specific antigens have shown promising clinical outcomes in a randomized trial in metastatic androgen independent prostate cancer. Other vaccine approaches include granulocyte-macrophage colony-stimulating factor modified tumor cell vaccines and poxvirus vaccines. A combination of vaccines with chemotherapy, radiotherapy, and other biologic agents is also being evaluated. Efforts to optimize vaccine approaches and select ideal patient populations need to continue because there is no evidence supporting a single superior approach.
疫苗免疫疗法是一种用于治疗前列腺癌的新型、靶向无毒治疗方式。在传统观念中被认为对免疫疗法难治的肿瘤中，已诱导出针对候选前列腺癌抗原的全身免疫反应。表达前列腺特异性抗原的自体树突状细胞疫苗在转移性雄激素非依赖性前列腺癌的一项随机试验中显示出了有前景的临床结果。其他疫苗方法包括粒细胞-巨噬细胞集落刺激因子修饰的肿瘤细胞疫苗和痘病毒疫苗。疫苗与化疗、放疗及其他生物制剂的联合应用也在评估之中。由于没有证据支持单一的优越方法，因此需要继续努力优化疫苗方法并选择理想的患者群体。
